ES2621664T3 - Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico - Google Patents

Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico Download PDF

Info

Publication number
ES2621664T3
ES2621664T3 ES12846895.6T ES12846895T ES2621664T3 ES 2621664 T3 ES2621664 T3 ES 2621664T3 ES 12846895 T ES12846895 T ES 12846895T ES 2621664 T3 ES2621664 T3 ES 2621664T3
Authority
ES
Spain
Prior art keywords
dihydroquinolin
cyclopropylamino
fluoroethyl
fluoro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12846895.6T
Other languages
English (en)
Spanish (es)
Inventor
Ichiro Araya
Akinori Goto
Wataru Minagawa
Keiko Funada
Muneki Nagao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2621664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2621664T3 publication Critical patent/ES2621664T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES12846895.6T 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico Active ES2621664T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011246209 2011-11-10
JP2011246209 2011-11-10
JP2012071739 2012-03-27
JP2012071739 2012-03-27
PCT/JP2012/007195 WO2013069297A1 (ja) 2011-11-10 2012-11-09 7-{(3s、4s)-3-[(シクロプロピルアミノ)メチル]-4-フルオロピロリジン-1-イル}-6-フルオロ-1-(2-フルオロエチル)-8-メトキシ-4-オキソ-1、4-ジヒドロキノリン-3-カルボン酸の結晶

Publications (1)

Publication Number Publication Date
ES2621664T3 true ES2621664T3 (es) 2017-07-04

Family

ID=48289529

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12846895.6T Active ES2621664T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico
ES16177827T Active ES2747303T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16177827T Active ES2747303T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico

Country Status (17)

Country Link
US (3) US9090587B2 (enExample)
EP (2) EP3112359B1 (enExample)
JP (4) JP5871948B2 (enExample)
KR (2) KR102162208B1 (enExample)
CN (2) CN104945375B (enExample)
AU (1) AU2016273899B2 (enExample)
BR (1) BR112014010765B1 (enExample)
CA (1) CA2855022C (enExample)
ES (2) ES2621664T3 (enExample)
IN (1) IN2014DN03277A (enExample)
MX (1) MX375073B (enExample)
NZ (1) NZ623808A (enExample)
RU (2) RU2615509C2 (enExample)
SA (1) SA112330992B1 (enExample)
SG (2) SG10201608167UA (enExample)
TW (1) TWI547492B (enExample)
WO (1) WO2013069297A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594418B2 (en) 2011-03-10 2026-04-07 Electrocore, Inc. Devices and methods for nerve stimulation
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
CN105338982B (zh) 2013-04-25 2017-10-10 杏林制药株式会社 固体药用组合物
JP6349306B2 (ja) * 2013-04-25 2018-06-27 杏林製薬株式会社 錠剤
US9687453B2 (en) 2013-04-25 2017-06-27 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JP6018334B2 (ja) * 2014-10-23 2016-11-02 杏林製薬株式会社 固形医薬組成物
EP3210608A4 (en) * 2014-10-23 2018-06-20 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
MX380385B (es) 2015-03-13 2025-03-12 Kyorin Seiyaku Kk Agente para el tratamiento de infeccion respiratoria.
WO2016195020A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
JP6031217B1 (ja) 2015-06-02 2016-11-24 杏林製薬株式会社 水性液剤
WO2016195014A1 (ja) * 2015-06-02 2016-12-08 杏林製薬株式会社 水性液剤
MY200429A (en) 2017-06-16 2023-12-26 Kyorin Seiyaku Kk Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
CA3067188A1 (en) 2017-06-16 2018-12-20 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
CN1158846A (zh) * 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
WO2003014732A1 (en) 2001-08-10 2003-02-20 Symyx Technologies, Inc. Apparatuses and methods for creating and testing pre-formulations and systems for same
AU2002236267A1 (en) * 2002-03-08 2003-09-22 Daiichi Pharmaceutical Co., Ltd. Quinolonecarboxylic acid derivative
PL1666477T3 (pl) 2003-09-10 2013-11-29 Kyorin Seiyaku Kk Pochodna kwasu 7-(4-podstawionego-3-cyklopropyloaminometylo-1- pirolidynylo)chinolonokarboksylowego
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Also Published As

Publication number Publication date
MX375073B (es) 2025-03-06
CN104945375B (zh) 2017-07-04
BR112014010765B1 (pt) 2020-07-14
BR112014010765A2 (pt) 2017-06-13
AU2012337206B2 (en) 2016-09-15
EP3112359A1 (en) 2017-01-04
EP2778159A4 (en) 2015-06-03
JP6514069B2 (ja) 2019-05-15
CN104945375A (zh) 2015-09-30
JP2016027045A (ja) 2016-02-18
US20150284361A1 (en) 2015-10-08
TWI547492B (zh) 2016-09-01
WO2013069297A1 (ja) 2013-05-16
KR102162208B1 (ko) 2020-10-06
AU2012337206A8 (en) 2016-09-22
CN103930414B (zh) 2016-01-20
RU2615509C2 (ru) 2017-04-05
CN103930414A (zh) 2014-07-16
US20140288310A1 (en) 2014-09-25
USRE47785E1 (en) 2019-12-31
RU2014123567A (ru) 2015-12-20
JP5871948B2 (ja) 2016-03-01
JP2018158949A (ja) 2018-10-11
JPWO2013069297A1 (ja) 2015-04-02
CA2855022A1 (en) 2013-05-16
AU2012337206A1 (en) 2014-05-22
AU2016273899A1 (en) 2017-01-12
ES2747303T3 (es) 2020-03-10
KR20190065456A (ko) 2019-06-11
EP3112359B1 (en) 2019-08-21
RU2017109814A (ru) 2019-01-23
SG11201401817TA (en) 2014-08-28
AU2016273899B2 (en) 2017-07-27
TW201332991A (zh) 2013-08-16
SA112330992B1 (ar) 2015-09-13
KR20140098074A (ko) 2014-08-07
US9090587B2 (en) 2015-07-28
JP2017160243A (ja) 2017-09-14
NZ623808A (en) 2015-07-31
RU2017109814A3 (enExample) 2020-04-08
IN2014DN03277A (enExample) 2015-05-22
US9328089B2 (en) 2016-05-03
CA2855022C (en) 2019-05-07
EP2778159A1 (en) 2014-09-17
SG10201608167UA (en) 2016-11-29
JP6818719B2 (ja) 2021-01-20
JP6349435B2 (ja) 2018-06-27
EP2778159B1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
ES2493940T3 (es) Una forma amorfa y una forma cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
HRP20241723T1 (hr) Kristalni toluen solvat od (s)-afoksolanera
US9328089B2 (en) 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-YL}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
RU2014110400A (ru) Способ и промежуточные соединения для получения макролактамов
ES2585221T3 (es) Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y productos intermedios sintéticos de la misma
CA2970500C (en) Piperidine derivatives as hdac1/2 inhibitors
ES2613716T3 (es) Formas cristalinas de un derivado de purina
JP2010513494A5 (enExample)
HRP20180970T1 (hr) Policiklični lpa1 antagonist i njegove primjene
Cheng et al. 7, 7′-diazaindirubin—a small molecule inhibitor of casein kinase 2 in vitro and in cells
TW200463B (enExample)
CN103709120B (zh) 一种盐酸阿考替胺三水合物的制备方法
EP4142707A1 (en) Inhibitors of alpha 2 beta 1 integrin and methods of use thereof
RU2015117524A (ru) Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция
ES2817909T3 (es) Procedimiento para la preparación de un intermedio de la sitagliptina mediante un método de reducción asimétrica
ES2543804T3 (es) Polimorfo B de Ibandronato
CN106255691A (zh) 4,5‑二氢‑1h‑吡咯并[2,3‑f]喹啉‑2,7,9‑三羧酸及其二钠盐的多晶型形式,其制备方法和用途
ES2554933T3 (es) Procedimiento de síntesis y forma cristalina de clorhidrato de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1H)-il]propoxi}benzamida, así como la base libre asociada y las composiciones farmacéuticas que los contienen
CN103467466A (zh) 一种盐酸莫西沙星杂质的合成方法
JP6230703B2 (ja) 4−ベンジル−1−フェネチル−ピペラジン−2,6−ジオンの製造方法、並びに、その中間体及び製造方法
ES2544988T3 (es) Procedimiento de obtención de la forma cristalina A del Febuxostat
CN118496163A (zh) 一种恩扎卢胺及其中间体的制备方法
CN105017147A (zh) 一种回收和利用Bedaquiline立体化学异构体的方法
ES2538880B1 (es) Un procedimiento para obtener 4-amino-1-isobutil-1H-imidazo[4,5-c]quinoleína
ME02735B (me) Nova sol 3- [ ( 3-{ [ 4- ( 4 - morfolinilmetil )-1 H- pirol- 2-il] metilen}- 2-okso-2,3-dihidro-1 H-indol-5- il)metil]-1,3-tiazolidin-2,4- dion, njihova priprava i formulacije koje ih sadržavaju